Hill Hearing Casts Spotlight On FDA Drug Approval Process
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Janet Woodcock defends the agency against criticism its review process is too slow; Congressman says FDA should proceed with antibiotic development program without waiting for new statutory authority.